Predictive Value of Sentinel Lymph Node Biopsy in Cutaneous Squamous Cell Carcinoma Based on the AJCC-8 and Brigham and Women's Hospital Staging Criteria

Dermatol Surg. 2020 Jul;46(7):857-862. doi: 10.1097/DSS.0000000000002170.

Abstract

Background: Recommendations on when to perform sentinel lymph node (SLN) biopsy in cutaneous squamous cell carcinoma (cSCC) are lacking despite the tumor's clear predilection for lymphatic spread.

Objective: To analyze the frequency of SLN metastasis in published series of cSCC in the context of the eighth edition of the American joint Committee on Cancer (AJCC-8) and the Brigham and Women's Hospital (BWH) staging criteria.

Methods: Systematic review of studies of patients with cSCC who underwent SLN biopsy that described biopsy results.

Results: In total, 153 patients with 24 positive SLN biopsies (15.7%) were included. Based on the AJCC-8 criteria positivity rates in the T2 and T3 categories were 8.3% (1/12 patients) and 25% (8/32), respectively. Using the BWH system there were, 2/33 in category T2a (6.5%), and 5/17 in category T2b (29.8%). On applying the same criteria to tumors of the trunk and extremities the results were similar.

Conclusion: It would seem reasonable to recommend SLN biopsy for patients with AJCC-8 Stage T3+ disease or BWH Stage T2b/T3 disease. Both the AJCC-8 and the BWH systems would appear to be useful for staging cSCC of the trunk and extremities.

Publication types

  • Systematic Review

MeSH terms

  • Carcinoma, Squamous Cell / pathology*
  • Humans
  • Neoplasm Staging / methods*
  • Predictive Value of Tests
  • Sentinel Lymph Node Biopsy*
  • Skin Neoplasms / pathology*